COPD and multimorbidity: recognising and addressing a syndemic occurrence
Most patients with chronic obstructive pulmonary disease (COPD) have at least one additional, clinically relevant chronic disease. Those with the most severe airflow obstruction will die from respiratory failure, but most patients with COPD die from non-respiratory disorders, particularly cardiovascular diseases and cancer. As many chronic diseases have shared risk factors (eg, ageing, smoking, pollution, inactivity, and poverty), we argue that a shift from the current paradigm in which COPD is considered as a single disease with comorbidities, to one in which COPD is considered as part of a multimorbid state—with co-occurring diseases potentially sharing pathobiological mechanisms—is needed to advance disease prevention, diagnosis, and management. The term syndemics is used to describe the co-occurrence of diseases with shared mechanisms and risk factors, a novel concept that we propose helps to explain the clustering of certain morbidities in patients diagnosed with COPD. A syndemics approach to understanding COPD could have important clinical implications, in which the complex disease presentations in these patients are addressed through proactive diagnosis, assessment of severity, and integrated management of the COPD multimorbid state, with a patient-centred rather than a single-disease approach.
Fuente original:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00261-8/fulltext#seccestitle10
Noticias relacionadas
RESPrimaria 1ª Edición: 8 de Mayo de 2024 en formato híbrido
Más de 900 sanitarios se reunirán de forma presencial y online, este miércoles en Barcelona, para mejorar la prevención y el tratamiento de las
patologías respiratorias.
TRIPLE THERAPY AND CLINICAL CONTROL IN B+ COPD PATIENTS: A PRAGMATIC, PROSPECTIVE, RANDOMIZED TRIAL
Treatment with LABA/LAMA is recommended in GOLD B patients. We hypothesized that triple therapy (LABA/LAMA/ICS) will be superior to LABA/LAMA in achieving and maintaining clinical control
COPD in the 21st Century
COPD in the 21st Century: Alvar Agustì and Rosa Faner are part of this book, being authors of chapter 4. Scientists and clinicians across many countries have made great efforts to understand this important disease, and these have yielded positive results.
Más artículos
COPD
- 759785·Richard Beasley et Al – Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
- 759788·Alvar Agustí, Rod Hughes, Eleni Rapsomaki, Barry Make, Ricardo Del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzen, Jørgen Vestbo, Hana Mullerova – The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
- 759883·Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí. – From treatable traits to GETomics in airway disease: moving towards clinical practice
- 768799·Surya P Bhatt Richard Casaburi Alvar Agusti et Al. Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
- 768885·Miguel Angel Martinez-García, Alvar Agustí. – Microbiological Monitoring in Therapeutic Trials in Chronic Obstructive Pulmonary Disease
Recuerda que puedes acceder a varios enlaces a artículos dentro de la categoría EPOC en esta web. También puedes acceder otros enlaces en el Listado de Artículos de la Cátedra de Salud Respiratoria.
Imagen obtenida en canva pro